Stockscreener 앱 받기
5.41
1.64%
-0.09
시장 영업 전:
5.49
0.08
+1.48%
전일 마감가:
$5.50
열려 있는:
$5.35
하루 거래량:
13.50M
Relative Volume:
0.56
시가총액:
$2.21B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.4903
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-1.81%
1개월 성능:
-19.01%
6개월 성능:
-19.97%
1년 성능:
-26.39%
1일 변동 폭
$5.28
$5.65
1주일 범위
$5.14
$5.89
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.41 | 2.21B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know - Nasdaq
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - MarketScreener
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - MarketScreener
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - MSN
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? - MSN
Recursion Pharma (RXRX) Stock Climbs Amid FDA Shift In Testing R - GuruFocus
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today - MSN
Biotech Revolution: FDA’s New Era Signals Dramatic Shift in Drug Development - macnifico.pt
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? - The Globe and Mail
Recursion Pharma rises, Intel & Five Below fall: Trending Tickers - Yahoo Finance
Recursion: FDA To Replace Animal Testing With AI?A Small But Necessary Win - Seeking Alpha
Recursion (RXRX) Utilizes AI for Enhanced Drug Discovery - GuruFocus
The AI Revolution in Biotech: Recursion Pharmaceuticals Soars 19.18% on FDA's New Approach to Animal Testing - RagingBull
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? - Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated - MSN
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study - Zacks Investment Research
Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform - TipRanks
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries - The Manila Times
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - MSN
Recursion Pharmaceuticals Strengthens Board with New Appointments - MSN
Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment - marketscreener.com
Recursion begins phase 1 study of lymphoma treatment - Investing.com
Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals - TipRanks
Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes - Yahoo Finance
Long Term Trading Analysis for (RXRX) - news.stocktradersdaily.com
Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market - Yahoo Finance
Recursion to Participate in Upcoming Investor Conference - Bluefield Daily Telegraph
Recursion stock hits 52-week low at $5.5 amid market challenges - Investing.com Canada
Recursion stock hits 52-week low at $5.5 amid market challenges By Investing.com - Investing.com South Africa
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):